MELBOURNE,Australia,Oct. 30,2024 -- Telix Pharmaceuticals Limited (ASX: TLX,Telix,the Company) today announces a partnership with California-based Subtle Medical,Inc. (Subtle Medical) for artificial intelligence(AI)-powered positron emission tomography (PET) imaging withTelix's commercial PSMA-PET[1] product,Illuccix® (68Ga-PSMA-11).
Subtle Medical's SubtlePET™is a U.S. Food and Drug Administration (FDA) cleared AI-driven solutionto enhance the efficiency and effectiveness of imaging procedures. The proprietary deep-learning algorithm allows for faster PET scanning – up to 75% time savings without compromising image quality. The technology represents a significant advancement in the field,offering numerous benefits to patients,physicians,and medical facilities.
SubtlePET's ability to expedite the imaging process reduces patient wait times and increases comfort,with the patient required to remain motionless under the camera for a shorter period of time,contributing to an overall more positive healthcare experience. Additionally,a shorter scan time for Illuccix will allow healthcare providers to further optimise workflows and resource utilisation.Most importantly for facilities,SubtlePET seamlessly integrates into existing imaging center workflows,empowering healthcare providers to achieve faster PET imaging on any scanner,regardless of manufacturer or model. The technology can also extend scanner life through improved performance.
Kevin Richardson,Chief Executive Officer,Telix Precision Medicine,said,"Through this partnership,we are excited to incorporate an innovative AI product into the Illuccix value proposition for our customers and the patients they serve. We believe that the combination of Illuccix and SubtlePET will further strengthen Telix's AI toolkit and also Illuccix's reputation as the best-in-class PSMA-PET imaging agent for accuracy,reliability,quality,and operational excellence in the U.S.As Telix looks to our future with a multi-product portfolio,we look forward to growing our partnership with Subtle Medical to advance patient care and more efficient PET workflows across the disease spectrum."
Josh Gurewitz,Chief Commercial Officer,Subtle Medical,commented,"We are pleased to commercially partner with Telix,a global leader in theranostics. This agreement represents a significant milestone for both companies,as we join forces to empower medical professionals and improve outcomes for patients with Subtle Medical's platform and innovative AI product for PET imaging,starting with prostate cancer."
The partnership with Telix,which covers North America and the European Union (EU,excluding France and French speaking Belgium),launches in the United States (U.S.) with Illuccix,with the aim to expand to other Telix PET-tracers,subject to regulatory approval.
To sign up for more information on Illuccix and SubtlePET visit https://illuccixhcp.com/power-of-lightning/
About Subtle Medical,Inc.
Subtle Medical is a leading innovator in medical imaging software,utilising advanced AI technologies to enhance the efficiency and effectiveness of imaging procedures. The company's solutions,SubtlePET™ and SubtleMR™,leverage proprietary algorithms to improve scan times and image quality,aiming to improve patient outcomes and the diagnostic process. SubtlePET has received 510(k) clearance from the FDA and is Conformité Européenne (CE) marked in the EU for use with multiple PET tracers. Subtle Medical is committed to transforming medical imaging through its cutting-edge solutions,making it faster,safer,and more accessible to patients worldwide. For more information,please visit www.subtlemedical.comor email sales@subtlemedical.com
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne,with international operations in the United States,Europe (Belgium and Switzerland),and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).
Telix's lead imaging product,gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®),has been approved by the U.S. FDA[2],by the Australian Therapeutic Goods Administration (TGA)[3],and by Health Canada[4].
Visit www.telixpharma.com for further information about Telix,including details of the latest share price,announcements made to the ASX,investor and analyst presentations,news releases,event details and other publications that may be of interest. You can also follow Telix on XandLinkedIn
Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com
Legal Notices
You should read this announcement together with our risk factors,as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX) or on our website.
The information contained in this announcement is not intended to be an offer for subscription,invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction,including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law,Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement,including any forward-looking statements (as referred to below),whether as a result of new information,future developments,a change in expectations or assumptions,or otherwise. No representation or warranty,express or implied,is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements that relate to anticipated future events,financial performance,plans,strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may","expect","intend","plan","estimate","anticipate","believe","outlook","forecast" and "guidance",or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks,uncertainties and other factors that may cause our actual results,levels of activity,performance or achievements to differ materially from any future results,performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial,market,regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business,forward-looking statements may include,but are not limited to,statements about: the initiation,timing,progress and results of Telix's preclinical and clinical trials,and Telix's research and development programs; Telix's ability to advance product candidates into,enrol and successfully complete,clinical studies,including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates,manufacturing activities and product marketing activities; Telix's sales,marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates,if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses,future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates,if and after they have been approved. Telix's actual results,performance or achievements may be materially different from those which may be expressed or implied by such statements,and the differences may be adverse. Accordingly,you should not place undue reliance on these forward-looking statements.
©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals® and Illuccix® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
[1] Imaging of prostate-specific membrane antigen with positron emissiontomography.
[2] Telix ASX disclosure 20 December 2021.
[3]Telix ASX disclosure 2 November 2021.
[4]Telix ASX disclosure 14 October 2022.